HT-ALZ / Hoth Therap - LARVOL DELTA

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours (PRNewswire) - "Hoth Therapeutics...announced groundbreaking preclinical data supporting the therapeutic potential of its lead Alzheimer's candidate, HT-ALZ, in improving cognitive function and reducing neuroinflammation in Alzheimer's disease (AD). HT-ALZ...has shown significant cognitive and behavioral benefits in APP/PS1 mouse models of Alzheimer's disease. The study demonstrated that chronic oral administration of HT-ALZ led to marked improvement in memory, reduction of anxiety-like behavior, and enhanced sensorimotor gating, all without impairing motor function. Crucially, HT-ALZ significantly decreased the number of GFAP-positive reactive astrocytes, key contributors to neuroinflammation and cognitive decline in AD."

Preclinical • Alzheimer's Disease

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer’s Program Using NK-1 Receptor Antagonist HT-ALZ (PRNewswire) - "Hoth Therapeutics...announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ-an FDA-approved NK-1 receptor antagonist-for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's disease (AD)....The proposal...aims to understand the precise neurological mechanisms and cellular targets responsible for the beneficial cognitive effects observed with HT-ALZ."

Licensing / partnership • Alzheimer's Disease

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway (PRNewswire) - "Hoth Therapeutics, Inc...is proud to announce the granting of a U.S. patent for its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent secures the company's intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials."

Patent • Alzheimer's Disease • CNS Disorders

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ (PRNewswire) - "The data showed a notable decrease in the percentage of area covered by astrocytes in the hippocampus at both 20 mg and 40 mg dose levels, compared to the vehicle- treated group. A similar trend was observed in the cortex. These reductions in reactive astrocytes corresponded with enhanced cognitive performance in the same dose groups, further indicating that aprepitant's therapeutic benefit may be tied to its impact on astrocytic activity...Hoth Therapeutics is currently conducting a secondary analysis to determine whether the size or total number of astrocytes is changing as a result of treatment. Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a potential breakthrough in the treatment of Alzheimer's."

Preclinical • Alzheimer's Disease • CNS Disorders

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment (PRNewswire) - "Hoth Therapeutics, Inc...today announced it has signed an agreement with LTS Therapy Systems, LLC ('LTS'), to develop and manufacture the HT-ALZ oral film prototype....The HT-ALZ prototype development and manufacturing work by LTS will be used to support a future Investigational New Drug (IND) Application to initiate clinical trials."

Licensing / partnership • Alzheimer's Disease • CNS Disorders

Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease (PRNewswire) - "Hoth Therapeutics, Inc...today announced that HT-ALZ, a therapeutic in development for the treatment of Alzheimer's Disease ("AD"), achieved positive preclinical end points in a study conducted at Washington University, St. Louis....Subjects treated with HT-ALZ show improvement on several tests of cognitive function, including spatial learning and memory, sensorimotor gating, and contextual associative memory. HT-ALZ showed positive benefits with reducing anxiety- like behavior in mice."

Preclinical • Alzheimer's Disease • CNS Disorders

Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease (PRNewswire) - "Hoth Therapeutics...today announced that HT-ALZ a therapeutic in development for the treatment of Alzheimer's disease achieved positive preclinical results that outpaced its pervious study. In particular, the higher dose appears to be most beneficial in a spatial memory test performed at Washington University in St Louis."

Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • Tauopathies And Synucleinopathies

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model (PRNewswire) - "Hoth Therapeutics, Inc...announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model (aged APP/PS1+/- mice), supporting the therapeutic cognitive potential of HT-ALZ after chronic oral dosing. The research was conducted as part of the company's Sponsored Research Agreement with Washington University in St. Louis. HT-ALZ is a therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of dementia related to Alzheimer's disease (AD)."

Preclinical • Alzheimer's Disease • CNS Disorders

Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ (PRNewswire) - “Hoth Therapeutics, Inc…announced that it has entered into an extension of its Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ, a novel therapeutic for the treatment of Alzheimer's disease….The chronic dosing studies will also include a broad range of HT-ALZ doses to determine if there are dose-dependent effects on behavioral outcomes. The outcome of these studies is to estimate a human equivalent dose for initiating clinical trials for HT-ALZ.”

Licensing / partnership • Alzheimer's Disease • CNS Disorders

Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference (PRNewswire) - “Hoth Therapeutics, Inc…announced an abstract submission to present the preclinical Alzheimer's disease mouse model data of HT-ALZ at the Alzheimer's Association International Conference taking place July 31 – August 4, 2022 in San Diego, California.”

Preclinical • Alzheimer's Disease • CNS Disorders